Skip to main content
Selumetinib CAS#: 606143-52-6
IdentificationPhysical DataSpectraRoute of Synthesis (ROS)Safety and HazardsOther Data

Identification

Product NameSelumetinibIUPAC Name6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamideMolecular StructureCAS Registry Number 606143-52-6EINECS Number207-313-3MDL NumberMFCD11977472SynonymsSelumetinib606143-52-6AZD6244ARRY-142886AZD 62445--4-FLUORO-N-(2-HYDROXYETHOXY)-1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXAMIDEAZD-6244ARRY 142886Selumetinib (AZD6244)ARRY-886selumetinibumUNII-6UH91I579U5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzoimidazole-6-carboxamide6UH91I579UARRY142886Selumetinib KoselugoDTXSID3048944CHEBI:902275-(4-broMo-2-chlorophenylaMino)-4-fluoro-N-(2-hydroxyethoxy)-1-Methyl-1H-benzoiMidazole-6-carboxaMideCHEMBL1614701DTXCID0028870NSC 741O78NSC741078NCGC00189073-01NCGC00189073-021H-Benzimidazole-6-carboxamide, 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-Benzimidazole-6-carboxamide, 5--4-fluoro-N-(2-hydroxyethoxy)-1-methyl-AZD6244 (Selumetinib)6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide5--4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-1,3-benzodiazole-6-carboxamide6--7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamideAZD 6244;5-((4-Bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzoimidazole-6-carboxamide;6-(4-bromo-2-chlorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzoimidazole-5-carboxamideCAS-606143-52-6C17H15BrClFN4O33EW5-((4-BROMO-2-CHLOROPHENYL)AMINO)-4-FLUORO-N-(2-HYDROXYETHOXY)-1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXAMIDESELUMETINIB SELUMETINIB Selumetinib (USAN/INN)SELUMETINIB MEK inhibitor AZD6244SELUMETINIB SCHEMBL155456GTPL5665EX-A020CYOHGALHFOKKQC-UHFFFAOYSA-NBCPP000367HMS3244G03HMS3244G04HMS3265K01HMS3265K02BCP01739Tox21_113362BDBM50355497MFCD11977472NSC800882s1008AKOS015904255Tox21_113362_1BCP9000354CCG-264774CS-0059DB11689EX-8621NSC-741078NSC-800882SB14707NCGC00189073-076-(4-bromo-2-chloro-anilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-benzimidazole-5-carboxamideAC-25059AM808016AZD6244,Selumetinib, ARRY-142886HY-50706Selumetinib (ARRY142886/AZD6244)AZD6244 (Selumetinib,ARRY-142886)A8446NS00071922SW202561-3D09666EN300-18166787Q-101405Q7448840BRD-K57080016-001-01-91H-BENZIMIDAZOLE-6-CARBOXAMIDE, 5-((4-BROMO-2-CHLOROPHENYL)AMINO)-4-FLUORO-N-(2- HYDROXYETHOXY)-1-METHYL-6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy -ethoxy)-amide6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid(2-hydroxy-ethoxy)-amide6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethoxy)-amide6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid(2-hydroxyethoxy)-amide6-(4-bromo-2chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amideMolecular FormulaC17H15BrClFN4O3 Molecular Weight457.7InChIInChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)InChI KeyCYOHGALHFOKKQC-UHFFFAOYSA-NIsomeric SMILESCCN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO

Patent InformationPatent IDTitlePublication DateCN109438362Substituted benzimidazole compound and composition with compound2019WO2018/65924INTERMEDIATES OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MAP2K OR MEK) INHIBITORS AND PROCESS FOR THEIR PREPARATION2018US2004/116710N3 alkylated benzimidazole derivatives as MEK inhibitors2004US2003/232869N3 alkylated benzimidazole derivatives as MEK inhibitors2003

Physical Data

AppearanceWhite or off-white powder.

Spectra

Description (NMR Spectroscopy)Nucleus (NMR Spectroscopy)Solvents (NMR Spectroscopy)Frequency (NMR Spectroscopy), MHzSolid state NMR, Chemical shifts, Spectrum19F3761HCD3OD40019FCD3OD3761HCD3OD

Route of Synthesis (ROS)

Route of Synthesis (ROS) of Selumetinib CAS# 606143-52-6

ConditionsYieldWith hydrogenchloride; water In ethanol for 24h;Experimental ProcedureHydrochloric acid (14 mL, 1.0 M aqueous solution, 14 mmol) was added to a suspension of 6-(4-bromo-2-chloro- phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboyxlic acid (2-vinyloxyethoxy)- amide (2.18 g, 4.50 mmol) in ethanol (50 mL) and the reaction mixture allowed to stir for 24 hours. The reaction mixture was concentrated to dryness by rotary evaporation and the solids partitioned between 3:1 ethyl acetate/tetrahydrofuran and saturated potassium carbonate. The aqueous phase was extracted with 3:1 ethyl acetate/tetrahydrofuran (3x), the combined organics dried (Na2SO4), and concentrated to provide 2.11 g (100%) 6-(4-bromo-2- chlorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2- hydroxyethoxy)-amide as an off-white solid. MS ESI (+) m/z 457, 459 (M+, Br pattern) detected. 1H NMR (400 MHz, MeOH-&0 δ 8.26 (s, IH), 7.78 (s, IH), 7.57 (d, IH), 7.24 (dd, IH), 6.40 (dd, IH), 3.86 (s, 3H), 3.79 (m, 2H), 3.49 (m, 2H). 19F NMR (376 MHz, MeOH-d4) -133.68 (s).100%With hydrogenchloride In ethanol; water at 25 - 30℃; for 24h;Experimental Procedure7 Example 7: Preparation of 5-H318 (100%): Causes serious eye damage H361 (100%): Suspected of damaging fertility or the unborn child H373 (100%): May causes damage to organs through prolonged or repeated exposure H411 (100%): Toxic to aquatic life with long lasting effects Precautionary Statement CodesP203, P260, P261, P264+P265, P272, P273, P280, P302+P352, P305+P354+P338, P317, P318, P319, P321, P333+P317, P362+P364, P391, P405, and P501(The corresponding statement to each P-code can be found at the GHS Classification page.)

Other Data

TransportationHS CodeStorageUnder the room temperature and away from lightShelf Life2 yearsMarket Price

DruglikenessLipinski rules componentMolecular Weight457.687logP3.696HBA5HBD3Matching Lipinski Rules4Veber rules componentPolar Surface Area (PSA)88.41Rotatable Bond (RotB)7Matching Veber Rules2

Use Pattern Selumetinib CAS#: 606143-52-6 is used for the treatment of advanced non-small cell lung cancer (NSCLC). Selumetinib primarily inhibits the growth of various tumors, including melanomas with B-Raf mutations and non-small cell lung cancer (NSCLC) with K-Ras mutations, by regulating the key protein kinase MEK in the Ras-Raf-MEK-ERK pathway. It is mainly employed in the treatment of diseases such as cholangiocarcinoma, colorectal cancer, and NSCLC. Currently, Selumetinib is in phase III clinical trials for the treatment of non-small cell lung cancer.
https://www.chemwhat.com/selumetinib-cas-606143-52-6/

Comments

Post a Comment

Popular posts from this blog

BCB (Benzocyclobutene): — Watson International Enables the Transition from Concept to Scalable Application

Benzocyclobutene (BCB) is an organic compound with a rigid molecular structure composed of a conjugated benzene ring and a four-membered ring. Its excellent thermal stability and electrical properties have made it a highly promising candidate for next-generation electronic materials. Historically, its industrial adoption has been constrained by high production costs, complex purification processes, and limited output. However, with growing demand in high-end applications and recent advances in upstream technology, BCB is now poised for industrial-scale deployment. Material Properties and Structural Advantages BCB (C₈H₈) is a non-polar molecule, free of ester, carboxyl, or amide groups, giving it excellent dielectric properties and low moisture absorption. Its dielectric constant (Dk) and dissipation factor (Df) remain stable across wide temperature and frequency ranges—key metrics for ensuring signal integrity in high-frequency, high-speed communication systems. Unlike conventional m...
Post a Comment
Read more

BCB (Benzocyclobutene): — Watson International Enables the Transition from Concept to Scalable Application

Despite BCB’s well-established performance advantages, its commercialization has long been hindered by production cost and scalability challenges. Watson International has made critical breakthroughs in BCB industrialization through integrated innovation in synthesis, purification, and material formulation: Cost Reduction: By optimizing synthetic pathways and improving by-product recovery, Watson has significantly reduced the unit production cost of BCB, enabling cost-effective scaling; High Purity Production: Advanced purification and process control technologies ensure high-purity BCB under mass-production conditions—meeting stringent requirements from high-end electronic manufacturers; Versatile Co-polymerization: Watson’s BCB materials are compatible with other advanced resins such as BMI and PPO, allowing for custom co-polymer design and performance tuning.
Post a Comment
Read more

The World's Largest Producer of Squaric Acid Emerges: Watson Leads the Way

In a groundbreaking development for the chemical industry, Watson has officially claimed the title of the world’s largest producer of squaric acid. This achievement marks a significant milestone, positioning the company as a global leader in the production of this highly versatile compound, widely valued in pharmaceuticals, polymer research, and advanced materials. What is Squaric Acid? Squaric acid, also known as quadratic acid, is a four-carbon cyclic diketone with two ketone groups and two hydroxyl groups arranged symmetrically. It is renowned for its stability and strong acidity, making it a unique compound in both organic and inorganic chemistry. Its derivatives find applications in creating advanced coatings, conductive polymers, and as intermediates in drug synthesis. Watson: Redefining Excellence in Squaric Acid Production Watson’s rise to the top of the squaric acid industry is backed by its unmatched production capacity, cutting-edge technology, and unwavering commitment...
Post a Comment
Read more